Dr. Shankar Musunuri, PhD, MBA is Chairman, CEO, and Co-Founder of Ocugen. Ocugen (NASDAQ: OCGN) is a publicly traded biotechnology company dedicated to bringing game-changing gene and cell therapies and vaccines to market and working even harder to provide access to patients globally. Dr. Musunuri transformed Ocugen from a start-up into a pioneering biotechnology leader in ophthalmology gene therapy with its novel modifier gene platform to treat all major blindness diseases. Dr. Musunuri is a seasoned biotech veteran with 30+ years’ experience advancing and commercializing a diverse portfolio of products. Prior to co-founding Ocugen in 2013, he held leadership roles at numerous companies ranging from large multinational biotechnology companies such as Wyeth and Pfizer to start-up biotech companies. During his 15 years at Pfizer, he gained extensive product launch and life-cycle management experience including leading the Global Operations Team for Prevnar 13, the world’s best-selling vaccine. Dr. Musunuri then founded Nuron Biotech, Inc., which grew into a commercial company in less than three years. Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut—where he also received a Distinguished Alumnus Award. He received his MBA from Duke University, where today he serves on the University’s Innovation & Entrepreneurship Board of Advisors. Dr. Musunuri has a passion for addressing diseases and conditions that lack effective treatments. This commitment is reflected in Ocugen’s relentless pursuit of courageous innovation on behalf of patients with unmet medical needs.